Abstract Number: 1149 • ACR Convergence 2021
Efficacy of Alendronate for Prevention of New Fractures and Vertebral Deformities in Patients with Rheumatologic Disorders on Chronic Glucocorticoid Therapy: A Systematic Review and Meta-analysis
Background/Purpose: Glucocorticoids are commonly used in patients with rheumatologic conditions including but not limited to Rheumatoid Arthritis, Polymyalgia Rheumatica, Systemic Lupus Erythematous and so on.…Abstract Number: 1875 • 2019 ACR/ARP Annual Meeting
Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study
Background/Purpose: There are limited data on patients transitioning from denosumab (DMAb) to bisphosphonates (BPs). The Denosumab Adherence Preference Satisfaction (DAPS) study (NCT00518531) reported that alendronate…Abstract Number: 2657 • 2019 ACR/ARP Annual Meeting
The Association Between Bisphosphonates and Giant Cell Arteritis: A Retrospective Cohort Study
Background/Purpose: Bisphosphonates have been used to treat disorders of bone metabolism for several years. A common adverse reaction associated with their use constitutes a transient…Abstract Number: 293 • 2018 ACR/ARHP Annual Meeting
Temporal Trends and Factors Associated with Bisphosphonate Drug Holidays
Background/Purpose: Safety concerns related to osteoporosis (OP) medication use and temporary or permanent cessation of bisphosphonate therapy (e.g. ‘drug holidays’) have generated appreciable attention in…Abstract Number: 1256 • 2018 ACR/ARHP Annual Meeting
A Customized Health Information Technology Effectively Identifies and Directs Bone Health Services in Rural Veterans with Osteoporosis Risk Factors
Background/Purpose: Osteoporosis is underdiagnosed and undertreated in the Veterans Health Administration (VHA), especially in rural Veterans. Tools to identify risk factors in Veterans are available.…Abstract Number: 1818 • 2018 ACR/ARHP Annual Meeting
Greater BMD Gains with Denosumab Vs Risedronate in Glucocorticoid-Treated Subjects: Results from the Final 24-Month Analysis of a Randomized, Double-Blind, Double-Dummy Study
Background/Purpose: Denosumab 60 mg subcutaneously every 6 months (Q6M) increased spine and hip BMD significantly more than risedronate 5 mg orally once daily (QD) at…Abstract Number: 2299 • 2018 ACR/ARHP Annual Meeting
Subgroup Analysis of the Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 24 Months in Glucocorticoid-Treated Individuals
Background/Purpose: We previously demonstrated that denosumab increased lumbar spine and total hip bone mineral density (BMD) significantly more than risedronate at 12 and 24 months…Abstract Number: 2808 • 2018 ACR/ARHP Annual Meeting
T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial
Background/Purpose: BMD is a strong predictor of fracture risk in untreated patients. Recent evidence suggests that BMD achieved during treatment also reflects fracture risk; thus,…Abstract Number: 2812 • 2018 ACR/ARHP Annual Meeting
Evaluation of Cortical Microarchitecture, Bone Stiffness and Bone Remodeling in Patients with Atypical Femoral Fracture
Background/Purpose: Atypical femoral fractures (AFF) are low energy femoral fractures and subtrochanteric/diaphyseal localization that have been related to long-term bisphosphonate therapy. Patients with AFF exhibit…Abstract Number: 48 • 2017 ACR/ARHP Annual Meeting
Modulation of Subchondral Bone Turnover Is Associated with Alteration of Cartilage Tissue Quality
Background/Purpose: Osteochondral unit is a bio composite responsible for an optimal distribution of load during movements and axial compression of a joint. Any alteration of…Abstract Number: 320 • 2017 ACR/ARHP Annual Meeting
Teriparatide Compared with Risedronate and the Risk of Clinical Vertebral Fractures: 2-Year Results of a Randomized, Double-Dummy Clinical Trial
Background/Purpose: The VERO trial was an active-controlled fracture endpoint clinical trial that recruited postmenopausal women with low bone mass and prevalent vertebral fractures (VFx). We…Abstract Number: 321 • 2017 ACR/ARHP Annual Meeting
A Meta-Analysis of 4 Clinical Trials of Denosumab Compared with Bisphosphonates in Postmenopausal Women Previously Treated with Oral Bisphosphonates
Background/Purpose: Four clinical trials have separately shown greater BMD gains with transitioning to denosumab (DMAb) compared with continuing on bisphosphonates (BP) in subjects previously treated…Abstract Number: 325 • 2017 ACR/ARHP Annual Meeting
Zoledronic Acid Did Not Impaired Renal Function in Patients with Osteoporosis
Background/Purpose: Bisphosphonates are recommended for patients with osteoporosis, however concerns have been raised with regards to their effect on kidney function. The aim of this…Abstract Number: 333 • 2017 ACR/ARHP Annual Meeting
Atypical Femoral Fracture in Patients of a Rheumatology Service: Clinical, Radiographic and Bone Histomorphometric Data
Background/Purpose: Atypical femoral fractures (AFF) are low energy femoral fractures with a specific radiographic pattern and subtrochanteric / diaphyseal localization that have been related to…Abstract Number: 828 • 2017 ACR/ARHP Annual Meeting
The Impact of the Duration of Bisphosphonate Drug Holidays on Hip Fracture Rates
Background/Purpose: Given FDA warnings, drug holidays (temporary or permanent discontinuation) of bisphosphonates (BPs) after long-term (3-5 years) continuous therapy is becoming increasingly common in the…
- 1
- 2
- 3
- 4
- Next Page »